8 results match your criteria: "From the National Centre for Immunisation Research and Surveillance[Affiliation]"
Clinical and Epidemiologic Profile of Invasive Pneumococcal Disease in Australian Children Following the Relaxation of Nonpharmaceutical Interventions Against SARS-COV-2.
Pediatr Infect Dis J
September 2023
From the National Centre for Immunisation Research and Surveillance, New South Wales, Australia.
Article Synopsis
- A global increase in invasive pneumococcal disease (IPD) among children has been observed, particularly in Australia after COVID-19 restrictions were eased.
- The analysis highlights severe health impacts from IPD, even in vaccinated children without prior health issues.
- Notably, nearly 50% of IPD cases were caused by serotypes not included in the 13-valent pneumococcal conjugate vaccine.
Severity of Rotavirus-Vaccine-Associated Intussusception: Prospective Hospital-Based Surveillance, Australia, 2007-2018.
Pediatr Infect Dis J
June 2022
From the National Centre for Immunisation Research and Surveillance, Westmead, New South Wales.
Background: Multiple studies have shown an association between intussusception (IS) and receipt of monovalent or pentavalent rotavirus vaccine (RV) in the previous 21 days. Disease severity is an important consideration for risk-benefit evaluations of RV, but no studies have compared the severity of IS within 21 days of vaccination (vaccine-associated, VA) and later (not temporally-associated, VNA).
Methods: We used active hospital-based surveillance in the Australian Paediatric Active Enhanced Disease Surveillance (PAEDS) network (July 2007 to February 2018) to identify infants ≤9 months of age meeting Brighton level 1 criteria for IS.
Pertussis Disease and Antenatal Vaccine Effectiveness in Australian Children.
Pediatr Infect Dis J
March 2022
From the National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia.
Article Synopsis
- A study analyzed hospitalized pertussis cases in Australia from 2012 to 2019, focusing on the effects of antenatal vaccination on severe pertussis cases in children aged 0 to 15 years.
- Results showed a significant decrease in cases under 2 months of age after the introduction of maternal vaccination, with vaccine effectiveness estimated at 84.3%.
- Despite high immunization rates, older children (12+ months) still accounted for a notable percentage of hospitalizations, highlighting the need for new vaccine strategies to further protect this age group.
Developmental outcomes following vaccine-proximate febrile seizures in children.
Neurology
July 2020
From the National Centre for Immunisation Research and Surveillance (L.D., N.W., K.M.), Children's Hospital Education Research Institute (B.B.), and Kids Neuroscience Centre (B.B.), The Children's Hospital at Westmead; University of Sydney Children's Hospital Westmead Clinical School (L.D., N.W., K.M., B.B.); Discipline of Paediatrics (M.G.), School of Medicine, Women's and Children's Hospital, University of Adelaide; Department of Paediatrics (N.C.), University of Melbourne, Royal Children's Hospital; Murdoch Children's Research Institute (N.C., J.B.), Parkville; Infection and Immunity (J.B.), Monash Children's Hospital, Department of Paediatrics, Monash Centre for Health Care Research and Implementation, Monash University, Clayton; Wesfarmer's Centre of Vaccines and Infectious Disease (P.R.), Telethon Kids Institute, West Perth; and School of Paediatrics and Child Health (P.R.), University of Western Australia, Perth, Australia.
Objective: To compare the developmental and behavioral outcomes of children experiencing an initial vaccine-proximate (VP) febrile seizure (FS) to those having a non-VP-FS (NVP-FS) and controls who have not had a seizure.
Methods: In this prospective multicenter cohort study, children with their first FS before 30 months of age between May 2013 and April 2016 were recruited from 4 Australian pediatric hospitals and classified as having VP-FS or NVP-FS. Similar-aged children with no seizure history were recruited as controls.
Long-term Vaccine Impact on Invasive Pneumococcal Disease Among Children With Significant Comorbidities in a Large Australian Birth Cohort.
Pediatr Infect Dis J
September 2019
From the National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases, Westmead, New South Wales, Australia.
Background: Little is known about long-term invasive pneumococcal disease (IPD) incidence in children with risk factors (RFs) in populations with high coverage pneumococcal conjugate vaccine (PCV) programs. We measured IPD burden and changes with PCV use in children by RF status.
Methods: A retrospective cohort of all live births in 2001-2012 in New South Wales, Australia was linked to IPD, hospitalization and death data.
Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers.
Pediatr Infect Dis J
December 2015
From the *National Centre for Immunisation Research and Surveillance (NCIRS), The Children's Hospital at Westmead, University of Sydney, Sydney, New South Wales, Australia; †Vaccine and Immunisation Research Group, Murdoch Children's Research Institute, University of Melbourne, Carlton, Australia; ‡School of Population and Global Health, University of Melbourne, Carlton, Australia; §Canberra Hospital, Woden, Canberra, Australia; ¶School of Paediatrics and Child Health, University of Western Australia, Perth, Australia; ‖Telethon Kids Institute, Perth, Australia; **Princess Margaret Hospital for Children, Perth, Australia; ††Vaccine Trials Group, University of Western Australia Centre for Child Health Research and Vaccine Trials Group, Telethon Kids Institute for Child Health Research, Perth, Australia; ‡‡Royal Children's Hospital, Brisbane, Queensland, Australia; §§School of Paediatrics and Reproductive Health, Robinson Research Institute, Women's and Children's Hospital, University of Adelaide, Adelaide, Australia; ¶¶GSK Vaccines, Wavre, Belgium; ‖‖GSK Pharmaceuticals Limited, Bangalore, Karnataka, India; and ***GSK Vaccines, King of Prussia, Philadelphia, Pennsylvania.
Background: Antibody persistence is evaluated in healthy Australian children 4 and 5 years postvaccination with a single dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine (Hib-MenC-TT) compared with separately administered Hib-TT and MenC-CRM197 vaccines (Hib + MCC).
Methods: This is another follow-up of a phase III, open, randomized, controlled study (NCT00326118), in which 433 Hib-primed but MenC naïve toddlers aged 12-18 months were randomized 3:1 to receive Hib-MenC-TT or Hib + MCC vaccines. Protection against (1) MenC was measured by serum bactericidal antibody assay using rabbit complement (rSBA) and (2) Hib was measured by enzyme-linked immunosorbent assay of antibodies to polyribosylribitol phosphate (anti-PRP).
Intussusception after monovalent human rotavirus vaccine in Australia: severity and comparison of using healthcare database records versus case confirmation to assess risk.
Pediatr Infect Dis J
September 2014
From the *National Centre for Immunisation Research and Surveillance (NCIRS), Westmead; †Discipline of Paediatrics and Child Health, University of Sydney; ‡Department of Microbiology and Infectious Diseases, The Children's Hospital at Westmead; §Immunisation Unit, NSW Ministry of Health; and ¶ Immunisation Unit, Health Protection, New South Wales, Australia.
Background: Surveillance for intussusception (IS) has been recommended in countries using rotavirus vaccine, but can be resource intensive. There is little data about the relative severity of rotavirus vaccine-associated IS compared with other IS cases. We collected detailed clinical data on all cases to evaluate the validity of ICD coding for IS in routinely collected data and case severity.
View Article and Find Full Text PDFAntibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth.
Pediatr Infect Dis J
May 2014
From the *National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead and the University of Sydney, New South Wales; †The Children's Hospital, Westmead, Sydney; ‡The University of Sydney, New South Wales, Australia; §Discipline of Paediatrics, School of Paediatrics and Reproductive Health and the Robinson Institute, The University of Adelaide; ¶Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, Women's and Children's Health Network, South Australia; ‖Telethon Institute for Child Health Research and Centre for Child Health Research, Faculty of Medicine and Dentistry, The University of Western Australia, Perth; and **Queensland Children's Medical Research Institute, University of Queensland, Brisbane, Queensland, Australia.
Background: In a previous study, we found that monovalent acellular pertussis (aP) vaccine at birth and 1 month achieves higher IgG antibody (Ab) levels to pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin by 8 weeks, when compared with controls. Here, we report antibody and cell-mediated immune responses to 4 years of age.
Methods: IgG Ab to PT, filamentous hemagglutinin and pertactin, diphtheria (D) and tetanus (T) was measured in the 3 groups (aP vaccine at birth and 1 month, aP birth only and no aP) at 2 years of age and before and after DTaP-inactivated polio vaccine (DTaP-IPV) at 4 years of age.